Japan· JP-2190036F1026
スクロオキシ水酸化鉄
A saccharated iron oxide product containing スクロオキシ水酸化鉄, registered in Japan by キッセイ薬品工業, on the national reimbursement list. The same ATC class is registered in 4 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Saccharated iron oxide is registered in 4 of 19 countries.
Countries holding a registration under ATC B03AB02 (saccharated iron oxide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 2 of them publish a price we can compare per daily dose
Saccharated iron oxide · ATC B03AB02
4 / 19 countries
- Belgiumprice
- Ireland
- Japan
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- スクロオキシ水酸化鉄
- Manufacturer
- キッセイ薬品工業
- Country
- Japan (JP)
- ATC code
- B03AB02
- ATC class
- Saccharated iron oxide
- Defined daily dose
- 0.11 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
41 interactions on record for saccharated iron oxide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Saccharated iron oxide · interactions on record
41 records
- 3 severe
- 38 moderate
Most severe, free to view
- ErdafitinibL01EN01severe
- ErdafitinibL01EX16severe
- DimercaprolV03AB09severe
- ErgocalciferolA11CC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Saccharated iron oxide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVelphoro 500 mg comprimidos masticablesVifor Fresenius Medical Care Renal Pharma France
- BelgiumVelphoro 125 mgVifor Fresenius Medical Care Renal Pharma France
- IcelandVelphoroVifor Fresenius Medical Care Renal Pharma France*
- SwedenVelphoro 125 mg Oralt pulver i dospåseVifor Fresenius Medical Care Renal Pharma France
- United StatesVelphoroFresenius Medical Care Renal Therapies Group, LLC
- ItalyVELPHORO*90 cpr mast 500 mg flaconeVIFOR FRESENIUS M.C.R.P.FRANCE
- FranceVELPHORO 500 mg, comprimé à croquerVIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
- NorwayVelphoroVifor Fresenius Medical Care Renal Pharma France (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Velphoro
- Liechtenstein · Velphoro
- Norway · Velphoro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1e798ea9-4485-4a2d-9ae9-7af2f9c82a3f GET /v1/drugs/1e798ea9-4485-4a2d-9ae9-7af2f9c82a3f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "250mg1錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2190036F1026",
"category": "内用薬",
"price_yen": 136.1,
"generic_name": "スクロオキシ水酸化鉄",
"product_name_jp": null,
"therapeutic_class": "2190",
"transitional_expiry": null
}See everything about saccharated iron oxide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.